- Home
- IGMS vs PACB Comparison
IGMS vs PACB Comparison
Compare IGMS & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- PACB
- Stock Information
- Founded
- IGMS 1993
- PACB 2000
- Country
- IGMS United States
- PACB United States
- Employees
- IGMS N/A
- PACB N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- IGMS Health Care
- PACB Industrials
- Exchange
- IGMS Nasdaq
- PACB Nasdaq
- Market Cap
- IGMS 528.6M
- PACB 452.1M
- IPO Year
- IGMS 2019
- PACB 2010
- Fundamental
- Price
- IGMS $7.48
- PACB $1.97
- Analyst Decision
- IGMS Buy
- PACB Buy
- Analyst Count
- IGMS 8
- PACB 15
- Target Price
- IGMS $16.25
- PACB $2.92
- AVG Volume (30 Days)
- IGMS 213.0K
- PACB 9.2M
- Earning Date
- IGMS 11-08-2024
- PACB 02-13-2025
- Dividend Yield
- IGMS N/A
- PACB N/A
- EPS Growth
- IGMS N/A
- PACB N/A
- EPS
- IGMS N/A
- PACB N/A
- Revenue
- IGMS $2,918,000.00
- PACB $173,147,000.00
- Revenue This Year
- IGMS $386.95
- PACB N/A
- Revenue Next Year
- IGMS N/A
- PACB $22.06
- P/E Ratio
- IGMS N/A
- PACB N/A
- Revenue Growth
- IGMS 57.64
- PACB 2.14
- 52 Week Low
- IGMS $6.17
- PACB $1.16
- 52 Week High
- IGMS $22.50
- PACB $10.65
- Technical
- Relative Strength Index (RSI)
- IGMS 31.94
- PACB 48.84
- Support Level
- IGMS $7.00
- PACB $1.88
- Resistance Level
- IGMS $10.80
- PACB $2.13
- Average True Range (ATR)
- IGMS 1.02
- PACB 0.21
- MACD
- IGMS -0.10
- PACB 0.00
- Stochastic Oscillator
- IGMS 10.39
- PACB 31.94
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.